Serotonergic modulation of face-emotion recognition

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 4, 2008, Pages 263-269

  Del Ben, C M ^a   Ferreira, C A Q ^a   Alves Neto, W C ^a   Graeff, F G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Defensive behavior; Facial expressions; Serotonin

Indexed keywords

SEROTONIN;

ANGER; BEHAVIOR; DEFENSIVE BEHAVIOR; EMOTION; FACIAL EXPRESSION; FEAR; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; PERCEPTION; RECOGNITION; REVIEW; SEROTONINERGIC SYSTEM; THREAT;

EID: 44449105481     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008000400002     Document Type: Review

References (43)

1. Blanchard DC, Griebel G, Blanchard RJ. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 2003; 463: 97-116.
2. Gray JA, McNaughton N. The neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. 2nd edn. Oxford: Oxford University Press; 2000.
3. Deakin JFW, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol 1991; 5: 305-315.
4. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996; 54: 129-141.
5. McNaughton N, Corr PJ. A two-dimensional neuropsychology of defense: fear/anxiety and defensive distance. Neurosci Biobehav Rev 2004; 28: 285-305.
6. Breiter HC, Etcoff NL, Whalen PJ, Kennedy WA, Rauch SL, Buckner RL, et al. Response and habituation of the human amygdala during visual processing of facial expression. Neuron 1996; 17: 875-887.
7. Phillips ML, Young AW, Senior C, Brammer M, Andrew C, Calder AJ, et al. A specific neural substrate for perceiving facial expressions of disgust. Nature 1997; 389: 495-498.
8. Whalen PJ, Shin LM, McInerney SC, Fischer H, Wright CI, Rauch SL. A functional MRI study of human amygdala responses to facial expressions of fear versus anger. Emotion 2001; 1: 70-83.
9. Fitzgerald DA, Angstadt M, Jelsone LM, Nathan PJ, Phan KL. Beyond threat: amygdala reactivity across multiple expressions of facial affect. Neuroimage 2006; 30: 1441-1448.
10. Sprengelmeyer R, Rausch M, Eysel UT, Przuntek H. Neural structures associated with recognition of facial expressions of basic emotions. Proc Biol Sci 1998; 265: 1927-1931.
11. Yang TT, Menon V, Eliez S, Blasey C, White CD, Reid AJ, et al. Amygdalar activation associated with positive and negative facial expressions. Neuroreport 2002; 13: 1737-1741.
12. Surguladze SA, Brammer MJ, Young AW, Andrew C, Travis MJ, Williams SC, et al. A preferential increase in the extrastriate response to signals of danger. Neuroimage 2003; 19: 1317-1328.
13. Hariri AR, Bookheimer SY, Mazziotta JC. Modulating emotional responses: effects of a neocortical network on the limbic system. Neuroreport 2000; 11: 43-48.
14. Whalen PJ. Fear, vigilance, and ambiguity: initial neuroimaging studies of the human amygdala. Curr Dir Psychol Sci 1998; 7: 177-188.
15. Attenburrow MJ, Williams C, Oclontiadis J, Reed A, Powell J, Cowen PJ, et al. Acute administration of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology 2003; 169: 104-107.
16. Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ. Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. Am J Psychiatry 2004; 161: 166-168.
17. Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ. A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol 2007; 21: 684-690.
18. Cools R, Calder AJ, Lawrence AD, Clark L, Bullmore E, Robbins TW. Individual differences in threat sensitivity predict serotonergic modulation of amygdala response to fearful faces. Psychopharmacology 2005; 180: 670-679.
19. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 2005; 30: 1724-1734.
20. Harmer CJ, Rogers RD, Tunbridge E, Cowen PJ, Goodwin GM. Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology 2003; 167: 411-417.
21. Harmer CJ, Bhagwagar Z, Perrett DI, Vollm BA, Cowen PJ, Goodwin GM. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 2003; 28: 148-152.
22. Harmer CJ, Reid CB, Ray MK, Goodwin GM, Cowen PJ. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology 2006; 186: 18-24.
23. Marsh AA, Finger EC, Buzas B, Soliman N, Richell RA, Vythilingham M, et al. Impaired recognition of fear facial expressions in 5-HTTLPR S-polymorphism carriers following tryptophan depletion. Psychopharmacology 2006; 189: 387-394.
24. van der Veen FM, Evers EA, Deutz NE, Schmitt JA. Effects of acute tryptophan depletion on mood and facial emotion perception related brain activation and performance in healthy women with and without a family history of depression. Neuropsychopharmacology 2007; 32: 216-224.
25. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM, Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 2004; 161: 1256-1263.
26. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006; 59: 816-820.
27. Murphy SE, Longhitano C, Ayres RE, Cowen PJ, Harmer CJ. Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers. Psychopharmacology 2006; 187: 121-130.
28. Hoshi R, Bisla J, Curran HV. The acute and sub-acute effects of 'ecstasy'(MDMA) on processing of facial expressions: preliminary findings. Drug Alcohol Depend 2004; 76: 297-304.
29. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxy-methamphetamine (MDMA or "Ecstasy"). Psychopharmacology 1995; 119: 247-260.
30. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 1998; 51: 215-235.
31. Kent JM, Coplan JD, Gorman JM. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 1998; 44: 812-824.
32. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992; 229: 101-103.
33. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 1995; 115: 1064-1070.
34. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 2003; 140: 1128-1136.
35. Felton TM, Kang TB, Hjorth S, Auerbach SB. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 297-305.
36. Moret C, Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 1996; 295: 189-197.
37. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 2001; 155: 323-326.
38. McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I, et al. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology 2005; 180: 680-686.
39. Stein MB, Simmons AN, Feinstein JS, Paulus MP. Increased amygdala and insula activation during emotion processing in anxiety-prone subjects. Am J Psychiatry 2007; 164: 318-327.
40. Phan KL, Fitzgerald DA, Nathan PJ, Tancer ME. Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry 2006; 59: 424-429.
41. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001; 50: 651-658.
42. Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004; 61: 877-889.
43. Cahill L. Why sex matters for neuroscience. Nat Rev Neurosci 2006; 7: 477-484.